Keywords
Treatment
Monoclonal antibodies
Children
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To discuss the new therapeutic measures used to treat Severe Asthma in children and adolescents, highlighting positive aspects and weaknesses, the mechanism of action of immunobiologicals, their effectiveness and safety. Methods: An integrative review of the literature was carried out using articles published in the last five years, available on the “Science direct”, “National Library of Medicine” and Virtual Health Library platforms. The search strategy returned 30 articles, of these 22 were included. Severe asthma, treatment, monoclonal antibodies, children were used as descriptors. Inclusion and exclusion criteria were listed. Results: After analyzing the selected studies, it was observed that the medications most used for this treatment provided an improvement in symptoms and a reduction in exacerbations and hospitalization of asthma in pediatric and adolescent patients. Conclusion: Recent studies on drugs highlight that immunobiologicals are promising for the treatment of moderate and severe asthma, bringing significant benefits to patient management, as they block or reduce the stimuli that trigger asthma symptoms, improving the expiratory volume requested in the first second (FEV1), reduce the possibility of worsening and are effective and safe for pediatric use.
References
ABUL MH, PHIPATANAKUL W. Severe asthma in children: evaluation and management. Allergology International, 2019; 68(2): 150-157.
AZMEH R, et al. Update in pediatric asthma: selected issues. Dis Mon., 2020; 66(4): 100886.
BACHARIER L, et al. Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study. The Journal of Allergy and Clinical Immunology, Estados Unidos, v. 12, ed. 4, p. 948-959, abril 2024.
CASTRO M, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med, 2011; 184: 1125-32.
CASTRO M, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med, 2015; 3: 355-66.
CHEN M, et al. No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities. Ann Allergy Asthma Immunol., Estados Unidos, ano 2020, n. 126, ed. 1, p. 666-673, Jan. 2021.
CHUNG KF. Visando a via das interleucinas no tratamento da asma. Lancet, 2015; 386: 1086–1096. DOI: 10.1016/s0140-6736 (15)00157-9.
CHUNG KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. Eur Respir J. 2014 Fev; 43(2): 343–73.
CORREN, JONATHAN et al. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. The Journal of Allergy and Clinical Immunology, Reino Unido, v. 8, ed. 2, p. 516-526, fevereiro 2020.
CORREN, JONATHAN et al. Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials. American Journal of Respiratory and Critical Care Medicine, Estados Unidos, v. 208, ed. 1, p. 13-24, julho de 2023.
DOROUDCHI A. et al. Asthma biologics: Comparing trial designs, patient cohorts and study results. Ann Allergy Asthma Immunol., 2020; 124(1): 44-56.
FARNE AH, et al. Anti-IL5 therapies for asthma. Cochrane Database Of Systematic Reviews, 2017; 9(9).
FIOCCHI, ALESSANDRO et al. Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study. European Respiratory Journal, Estados Unidos, v. 62, ed. 5, p. 1-10, novembro de 2023.
Global Initiative for Asthma. Global for Asthma Management and prevention (2024): https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf
JACKSON, DAVID et al. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma. Springer, Reino Unido, v. 37, ed. 12, p. 718-729, Dezembro 2019.
JUNIOR A, , et al. The multidisciplinary vision of the quality of life of asthma children. Brazilian Journal of Health Review, [S. l.], v. 3, n. 4, p. 8757–8766, 2020. DOI: 10.34119/bjhrv3n4-120.
KARDAS G. et al. Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives. Frontiers in Immunology, 2022; 13: 983852.
KOFI J, et al. National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. 2020 Focused updates to the asthma management guidelines [homepage]. Washington: U.S. Department of Health and Human.
LIBERATI A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine, 6(7), e1000100.
LICARI A, et al. Immunomodulation in Pediatric Asthma. Frontiers In Pediatrics, 2019. 7: 289.
LOVINSKY‐DESIR S. The use of biologic therapies for the management of pediatric asthma. Pediatric Pulmonology, 2019; 55(3): 803-808.
MCGREGOR M. C. et al. Role of Biologics in Asthma. American Journal of Respiratory and Critical Care Medicine, 2018; 199(4), 433-445.
MARQUES G. A.; Wendt A.; Wehrmeister F. C. Temporal evolution of and factors associated with asthma and wheezing in schoolchildren in Brazil. J bras pneumol, [Internet]. 2019; 45(3): e20180138.
MARQUES C, et al. Epidemiologia da Asma no Brasil, no período de 2016 a 2020. Research, Society and Development, [S. l.], v. 11, n. 8, p. e5211828825, 2022. DOI: 10.33448/rsd-v11i8.28825.
MIRRA V, et al. Pediatric severe asthma: a case series report and perspectives on anti-IgE treatment. BMC Pediatrics, 2018; 18(1).
NAIR PARAMESWARAN, et al. Efficacy of Intravenous Reslizumab in Oral Corticosteroid-Dependent Asthma. The Journal of Allergy and Clinical Immunology, Canadá, v. 8, ed. 2, p. 555-564, fevereiro de 2020.
NAKAMURA N, et al. Real-life long-term safety and effectiveness of omalizumab in Japanese pediatric patients with severe allergic asthma:A post-marketing surveillance. Japanese Society of Allergology, Japão, v. 70, n. 3, p. 319-326, Julho 2021
PAVORD ID, et al. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR). Ann. Allergy Asthma Immunol. 2023 Nov;131(5):587-597.e3. doi: 10.1016/j.anai.2023.08.015. Epub 2023 Aug 23. PMID: 37619779.
PAVORD IAN, et al. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma. The Journal of Allergy and Clinical Immunology, Reino Unido, v. 11, ed. 4, p. 1213-1220, abril 2023. (2)
PATEL SJ, Teach SJ. Asthma. Pediatr Rev., 2019; 40(11): 549-67.
SARINHO, FW et al. Guia prático para o uso de imunobiológicos em doenças alérgicas - ASBAI. Associação Brasileira de Alergia e Imunologia. Vol. 7, N° 4, 2023.
VOTTO M, et al. Biological Therapies in Children and Adolescents with Severe Uncontrolled Asthma: a practical review. Biologics: Targets and Therapy, 2021; 15: 133-142.
WEDNER H. JAMES, et al. Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study). Pediatric Allergy and Immunology, Estados Unidos, v. 35, ed. 3, p. 2-12, março 2024.
WALSH GM. Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma. Biologics, 2013; 7: 7-11.
ZHU Rui, et al. Population‐Based Pharmacodynamic Modeling of Omalizumab in Pediatric Patients with Moderate to Severe Persistent Inadequately Controlled Allergic Asthma. The AAPS Journal, Estados Unidos, v. 25, n. 56, p. 1-8, Jun. 2023.